These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 39017983)

  • 1. Clinical characteristics, diagnosis and management of nivolumab-induced myocarditis: hypersensitivity myocarditis, or something else.
    Kounis NG; Mplani V
    Invest New Drugs; 2024 Aug; 42(4):478-479. PubMed ID: 39017983
    [No Abstract]   [Full Text] [Related]  

  • 2. Ipilimumab- and nivolumab-induced myocarditis in a patient with metastatic cholangiocarcinoma: a case report.
    Delombaerde D; Vervloet D; Berwouts D; Beckers R; Prenen H; Peeters M; Gremonprez F; Croes L; Vulsteke C
    J Med Case Rep; 2022 Jul; 16(1):275. PubMed ID: 35831829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical characteristics, diagnosis and management of nivolumab-induced myocarditis.
    Li MT; He Y; Huang SY; Hu X; Chen JS
    Invest New Drugs; 2024 Feb; 42(1):116-126. PubMed ID: 38253746
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fulminant myocarditis induced by immune checkpoint inhibitor nivolumab: a case report and review of the literature.
    Wang F; Liu Y; Xu W; Zhang C; Lv J; Ma S
    J Med Case Rep; 2021 Jul; 15(1):336. PubMed ID: 34225811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Systematic Review of Myocarditis Induced by Immune Checkpoint Inhibitors: How Concerning Is the Most Common Cardiotoxicity of Immune Checkpoint Inhibitors?
    Moradi A; Kodali A; Okoye C; Klein DH; Mohamoud I; Olanisa OO; Parab P; Chaudhary P; Mukhtar S; Mohammed L
    Cureus; 2023 Jul; 15(7):e42071. PubMed ID: 37602125
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathophysiology, diagnosis and management of cardiac toxicity induced by immune checkpoint inhibitors and BRAF and MEK inhibitors.
    Arangalage D; Degrauwe N; Michielin O; Monney P; Özdemir BC
    Cancer Treat Rev; 2021 Nov; 100():102282. PubMed ID: 34438238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serial Troponin for Early Detection of Nivolumab Cardiotoxicity in Advanced Non-Small Cell Lung Cancer Patients.
    Sarocchi M; Grossi F; Arboscello E; Bellodi A; Genova C; Dal Bello MG; Rijavec E; Barletta G; Rossi G; Biello F; Ghigliotti G; Canepa M; Mussap M; Brunelli C; Spallarossa P
    Oncologist; 2018 Aug; 23(8):936-942. PubMed ID: 29567824
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Challenges and solutions in management of cardiotoxicity induced by checkpoint inhibitors.
    Mladosievičová B; Országhová Z; Jablonická M; Rečková M; Chovanec M; Mego M
    Klin Onkol; 2020; 33(5):350-355. PubMed ID: 33108879
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Smoldering myocarditis following immune checkpoint blockade.
    Norwood TG; Westbrook BC; Johnson DB; Litovsky SH; Terry NL; McKee SB; Gertler AS; Moslehi JJ; Conry RM
    J Immunother Cancer; 2017 Nov; 5(1):91. PubMed ID: 29157297
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunomodulatory treatment of immune checkpoint inhibitor-induced myocarditis: Pathway toward precision-based therapy.
    Balanescu DV; Donisan T; Palaskas N; Lopez-Mattei J; Kim PY; Buja LM; McNamara DM; Kobashigawa JA; Durand JB; Iliescu CA
    Cardiovasc Pathol; 2020; 47():107211. PubMed ID: 32268262
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Myocarditis in a patient treated with Nivolumab and PROSTVAC: a case report.
    Monge C; Maeng H; Brofferio A; Apolo AB; Sathya B; Arai AE; Gulley JL; Bilusic M
    J Immunother Cancer; 2018 Dec; 6(1):150. PubMed ID: 30563577
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative cardiotoxicity risk of pembrolizumab versus nivolumab in cancer patients undergoing immune checkpoint inhibitor therapy: A meta-analysis.
    Ndjana Lessomo FY; Wang Z; Mukuka C
    Front Oncol; 2023; 13():1080998. PubMed ID: 37064101
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nivolumab-induced fatal myocarditis: A case report.
    Bharathidasan K; Abdelnabi M; Abdelmalek J; Sekhon J; Butler W; Quirch M; Sosa EA
    Clin Case Rep; 2023 May; 11(5):e7306. PubMed ID: 37180331
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nivolumab and Ipilimumab-induced myositis and myocarditis mimicking a myasthenia gravis presentation.
    Valenti-Azcarate R; Esparragosa Vazquez I; Toledano Illan C; Idoate Gastearena MA; Gállego Pérez-Larraya J
    Neuromuscul Disord; 2020 Jan; 30(1):67-69. PubMed ID: 31839404
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Myocarditis as an immune-related adverse event following treatment with ipilimumab and nivolumab combination therapy for metastatic renal cell carcinoma: a case report.
    Miyauchi Y; Naito H; Tsunemori H; Tani R; Hasui Y; Miyake Y; Minamino T; Ishikawa R; Kushida Y; Haba R; Sugimoto M
    J Med Case Rep; 2021 Oct; 15(1):508. PubMed ID: 34649593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An Emergent Form of Cardiotoxicity: Acute Myocarditis Induced by Immune Checkpoint Inhibitors.
    Esposito R; Fedele T; Orefice S; Cuomo V; Prastaro M; Canonico ME; Ilardi F; De Stefano F; Fiorillo L; Santoro C; Esposito G
    Biomolecules; 2021 May; 11(6):. PubMed ID: 34067474
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An Autopsy Case of Late-onset Fulminant Myocarditis Induced by Nivolumab in Gastric Cancer.
    Naganuma K; Horita Y; Matsuo K; Miyama Y; Mihara Y; Yasuda M; Nakano S; Hamaguchi T
    Intern Med; 2022 Oct; 61(19):2867-2871. PubMed ID: 35249925
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fatal myocarditis after the first dose of nivolumab.
    Zomborska E; Kasperova S; Slopovsky J; Pazderová N; Kasperova B; Penz P; Nyitrayová O; Salek T; Porsok S; Mladosievicova B; Mego M
    Klin Onkol; 2022; 35(6):486-492. PubMed ID: 36513516
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiotoxicity of Immune Checkpoint Inhibitors.
    Patel RP; Parikh R; Gunturu KS; Tariq RZ; Dani SS; Ganatra S; Nohria A
    Curr Oncol Rep; 2021 May; 23(7):79. PubMed ID: 33937956
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nivolumab-induced Myositis and Myocarditis with Positive Anti-titin Antibody and Anti-voltage-gated Potassium Channel Kv1.4 Antibody.
    Ono R; Iwai Y; Yamazaki T; Takahashi H; Hori Y; Fukushima K; Saotome T
    Intern Med; 2022 Oct; 61(19):2973-2979. PubMed ID: 35314545
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.